Diagnosis and treatment of ALL in children and adults

This activity is older than 12 months.

This case series has been developed with the assistance of Elias Jabbour MD (MD Anderson Cancer Center, Houston, TX), Aaron Logan MD PhD (UCSF Health, San Francisco, CA), Patrick Brown MD (Johns Hopkins Medicine, Baltimore, MD), and Jae Park MD (Memorial Sloan Kettering Cancer Center, New York, NY). This activity was supported by Amgen.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient.

For full prescribing information, including indications, contraindications, warnings, precautions, and adverse effects, please refer to the approved product labeling. Please note that products may have different product labeling according to geographical location; full prescribing information is available from the US Food and Drug Administration through the “Drugs@FDA” portal and Licensed Biological Products page. Full prescribing information is also available from the Australian Therapeutic Goods Administration via the TGA portal (tga.gov.au/product-information-0).

All characters and events depicted in this patient case series are entirely fictitious. Any similarities to actual events or persons, living or dead, is purely coincidental. This activity is intended only for healthcare professionals registered to practice in the Asia-Pacific (APAC) region. To proceed, please confirm that you are a healthcare professional practicing in one of the aforementioned countries (APAC region).

Modules

• A 9-year-old boy with B-cell precursor acute lymphoblastic leukemia (ALL)

• A 65-year-old woman with Philadelphia-positive B-cell acute lymphoblastic leukemia

• A 50-year-old man with relapsed, Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL)